- Altimmune (ALT) stock sold off after the company announced its plan to scrap its COVID19 vaccine programs, and ALT is currently trading at an enterprise value of around US$120M.
- We believe ALT's NASH and obesity pipeline drives most of its value. The recent sell-off offers an attractive low-risk entry point for long-term investors.
- ALT-801's unique mechanism of action offers a compelling opportunity in the NASH and obesity space, which has an attractive + market size with high unmet need.
- We believe the phase 1 readout in Q4 2021 will further de-risk ALT-801, especially in the evidence of weight loss and tolerability.
For further details see:
Altimmune: NASH And Obesity At The End Of The COVID Tunnel